Misplaced Pages

TOL-463

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Combination drug Pharmaceutical compound
TOL-463
Boric acid (top) and EDTATooltip ethylenediaminetetraacetic acid (bottom)
Combination of
Boric acidAntiseptic, antifungal
EDTAAntimicrobial enhancer
Clinical data
Other namesBoric acid/ethylenediamine-tetraacetic acid; Boric acid/EDTA
Routes of
administration		Vaginal (insert, gel)

TOL-463 is an anti-infective medication which is under development for the treatment of bacterial vaginosis (BV) and vulvovaginal candidiasis (VVC) (vaginal yeast infection). It is a boric acid-based vaginal anti-infective enhanced with ethylenediaminetetraacetic acid (EDTA) which was designed to have improved activity against vaginal bacterial and fungal biofilms while sparing protective lactobacilli. EDTA enhances the antimicrobial activity of boric acid and improves its efficacy against relevant biofilms.

In a small phase 2 randomized controlled trial, TOL-463 as an insert or gel achieved clinical cure rates of 50 to 59% against BV and 81 to 92% against VVC in women who had one or both conditions. It was effective and safe in the study, though it was without indication of superiority over other antifungal medications for VVC. The cure rates against BV with TOL-463 were said to be comparable to those with recently approved antibiotic treatments like single-dose oral secnidazole (58%) and single-dose metronidazole vaginal gel (41%).

As of July 2022, TOL-463 is in phase 2 clinical trials for the treatment of BV and VVC. It was originated by Toltec Pharmaceuticals and is under development by Toltec Pharmaceuticals and the National Institute of Allergy and Infectious Diseases. There have been no developmental updates since May 2019.

See also

References

  1. ^ Marrazzo JM, Dombrowski JC, Wierzbicki MR, Perlowski C, Pontius A, Dithmer D, Schwebke J (February 2019). "Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial". Clin Infect Dis. 68 (5): 803–809. doi:10.1093/cid/ciy554. PMC 6376090. PMID 30184181.
  2. ^ Nyirjesy P, Brookhart C, Lazenby G, Schwebke J, Sobel JD (April 2022). "Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines". Clin Infect Dis. 74 (Suppl_2): S162–S168. doi:10.1093/cid/ciab1057. PMID 35416967.
  3. ^ "TOL 463 - AdisInsight".
  4. ^ Sobel JD, Sobel R (August 2021). "Current and emerging pharmacotherapy for recurrent bacterial vaginosis". Expert Opin Pharmacother. 22 (12): 1593–1600. doi:10.1080/14656566.2021.1904890. PMID 33750246. S2CID 232325625.

External links


Stub icon

This antiinfective drug article is a stub. You can help Misplaced Pages by expanding it.

Stub icon

This drug article relating to the genito-urinary system is a stub. You can help Misplaced Pages by expanding it.

Categories: